At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p<0.05) and total fat (-5%), stabilization ...
Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is ...
Wave Life Sciences Ltd. announced the completion of dosing in the first two cohorts of the INLIGHT trial for the obesity treatment WVE-007, with clinical data expected in the second half of 2025. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results